FDA Approves Drug to Reduce Heart Attack Risk in People With Type 2 Diabetes
Notably, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of serious cardiovascular events in adults with type 2 diabetes.
Notably, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of serious cardiovascular events in adults with type 2 diabetes.
Article outline
- What happened
- Why it matters
- The key numbers
- The bottom line
Key points
- Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.
- The study followed more than 13, 000 patients in 30 countries for five years.
- Kenneth Custer, president of Cardiometabolic Health at Eli Lilly, remarked heart disease is the leading cause of death in residents with type 2 diabetes.
- Add as a preferredSource on Google Follow on Google News Join WhatsApp.
- The decision was backed by results from SURPASS-CVOT, a major cardiovascular study that compared Mounjaro directly with Trulicity (dulaglutide).
Notably, the approval means Mounjaro can now be applied to lower the risk of heart attack, stroke and cardiovascular death in these patients.
Notably, the decision was backed by results from SURPASS-CVOT, a major cardiovascular study that compared Mounjaro directly with Trulicity (dulaglutide). Illegal Migration From Pakistan to Europe Drops by 64%.
In practice, the study followed more than 13, 000 patients in 30 countries for five years. Results indicated that patients taking Mounjaro had an 8% lower risk of cardiovascular death, heart attack or stroke compared with Trulicity.
Unlike cardiovascular trials that compare a treatment with a placebo, SURPASS-CVOT directly compared two incretin-based medicines.
Kenneth Custer, president of Cardiometabolic Health at Eli Lilly, remarked heart disease is the leading cause of death in residents with type 2 diabetes. He remarked Mounjaro can now assist these patients lower that risk.
Lilly remarked Mounjaro is the first and only medicine to target both GIP and GLP-1 receptors and reduce cardiovascular risk. It lowers the risk of heart attack, stroke and cardiovascular death in high-risk adults with type 2 diabetes. FDA Approves New Pancreatic Cancer Pill.
In practice, the study did not identify any major new safety reservations. While gastrointestinal challenges remained the most commonly noted side effects, the safety results were in line with previous Mounjaro studies. Most were mild to moderate.
In practice, the FDA approval expands Mounjaro's benefits for adults with type 2 diabetes. The drug can now additionally assist reduce the risk of serious cardiovascular events. Stay Connected with ProPakistani. Obtain the latest international news and global stories wherever you prefer. Follow on Google Discover.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories. Education specialist, covering exams, results, and admissions.
In short, FDA Approves Drug to Reduce Heart Attack Risk in People With Type is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.
